| Myriad meets 4Q profit forecasts | |
| | |
|
SALT LAKE CITY (AP) _ Myriad Genetics Inc. (MYGN) on Tuesday reported fiscal fourth-quarter net income of $18.7 million.
On a per-share basis, the Salt Lake City-based company said it had net income of 26 cents. Earnings, adjusted for one-time gains and costs, came to 41 cents per share.
The results met Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was also for earnings of 41 cents per share.
The molecular diagnostic company posted revenue of $189.9 million in the period, beating Street forecasts. Six analysts surveyed by Zacks expected $187.6 million.
For the year, the company reported profit of $80.2 million, or $1.08 per share. Revenue was reported as $723.1 million.
For the current quarter ending in October, Myriad expects its per-share earnings to range from 34 cents to 36 cents.
The company said it expects revenue in the range of $176 million to $178 million for the fiscal first quarter.
Myriad expects full-year earnings in the range of $1.60 to $1.65 per share, with revenue ranging from $750 million to $770 million.
Myriad shares have decreased roughly 9 percent since the beginning of the year. In the final minutes of trading on Tuesday, shares hit $31.08, a drop of 19 percent in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on MYGN at http://www.zacks.com/ap/MYGN
_____
Keywords: Myriad Genetics, Earnings Report
|
|
| |
ProfilIndicateurs de MarchéVALEUR : Projets & res.Communiqués de PresseRapport annuelRISQUE : Profile actifsContactez la cie |
Myriad Genetics est une société basée aux Etats-Unis D'Amerique. Myriad Genetics est cotée aux Etats-Unis D'Amerique. Sa capitalisation boursière aujourd'hui est 1,7 milliards US$ (1,6 milliards €). La valeur de son action a atteint son plus bas niveau récent le 29 mai 1998 à 10,00 US$, et son plus haut niveau récent le 17 novembre 2000 à 94,06 US$. Myriad Genetics possède 68 090 000 actions en circulation. |